Although recently the RESCUE trial reported a marked reduction in inflammation and thrombosis biomarkers with a novel IL-6 inhibitor [59] and previous studies showed a beneficial effect of immunomodulatory agents in cardiovascular outcomes [60,61], this effect was not identified in our analysis of patients hospitalized with COVID-19. Here, IL6 is linked to COVID-19.